Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$6.54M Buy
50,916
+5,709
+13% +$668K 0.28% 88
2026
Q1
$5.44M Buy
45,207
+11,324
+33% +$1.31M 0.27% 91
2025
Q4
$3.57M Buy
33,883
+4,666
+16% +$438K 0.18% 120
2025
Q3
$2.45M Buy
29,217
+6,681
+30% +$550K 0.15% 123
2025
Q2
$1.78M Sell
22,536
-23,115
-51% -$1.84M 0.17% 119
2025
Q1
$4.1M Buy
45,651
+5,981
+15% +$558K 0.25% 91
2024
Q4
$3.95M Sell
39,670
-2,597
-6% -$268K 0.25% 91
2024
Q3
$4.8M Buy
42,267
+760
+2% +$90.3K 0.33% 69
2024
Q2
$5.14M Buy
41,507
+1,702
+4% +$219K 0.38% 58
2024
Q1
$5.25M Buy
39,805
+3,894
+11% +$480K 0.41% 58
2023
Q4
$3.92M Sell
35,911
-498
-1% -$51.7K 0.33% 73
2023
Q3
$3.75M Buy
36,409
+15,239
+72% +$1.64M 0.38% 62
2023
Q2
$2.44M Buy
21,170
+8,554
+68% +$971K 0.31% 74
2023
Q1
$1.34M Sell
12,616
-3,108
-20% -$336K 0.22% 105
2022
Q4
$1.74M Buy
15,724
+2,161
+16% +$221K 0.32% 74
2022
Q3
$1.17M Sell
13,563
-1,015
-7% -$90.6K 0.29% 79
2022
Q2
$1.33M Sell
14,578
-2,934
-17% -$260K 0.29% 79
2022
Q1
$1.44M Buy
17,512
+1,136
+7% +$89.6K 0.3% 73
2021
Q4
$1.25M Sell
16,376
-1,024
-6% -$81.6K 0.27% 90
2021
Q3
$1.31M Sell
17,400
-5,621
-24% -$428K 0.33% 72
2021
Q2
$1.79M Buy
23,021
+10,026
+77% +$746K 0.49% 48
2021
Q1
$956K Buy
12,995
+1,811
+16% +$134K 0.43% 62
2020
Q4
$873K Buy
11,184
+557
+5% +$42.6K 0.43% 63
2020
Q3
$841K Sell
10,627
-48
-0.4% -$3.76K 0.47% 61
2020
Q2
$788K Buy
10,675
+1,234
+13% +$92.9K 0.42% 57
2020
Q1
$693K Sell
9,441
-15
-0.2% -$1.18K 0.46% 54
2019
Q4
$821K Buy
+9,456
New +$777K 0.5% 45

Other funds holding MRK

Procyon Advisors's MRK Position: Q2 2026 in Review

Procyon Advisors increased its Merck (MRK) stake by 13% in Q2 2026, buying an estimated $668K and bringing the position to 50,916 shares worth $6.54M. The position accounts for 0.28% of the portfolio, ranked #88.

Procyon Advisors first reported a position in MRK in Q4 2019 and has held it in 27 quarters since. 1,660 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Procyon Advisors held 50,916 shares of Merck worth $6.54M as of Q2 2026.
  • Procyon Advisors bought 5,709 Merck shares in Q2 2026, an estimated $668K.
  • Merck made up 0.28% of Procyon Advisors's portfolio in Q2 2026, its #88 holding.
  • Procyon Advisors first reported a position in Merck in Q4 2019 and has held it in 27 quarters since.
  • 1,660 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Procyon Advisors's 13F filing for Q2 2026, filed 9 Jul 2026.